Back to search

Article

A community-engaged mHealth intervention to increase uptake of HIV Pre-Exposure Prophylaxis (PrEP) among gay, bisexual and other men who have sex with men in China: Study protocol for a pilot randomized controlled trial

2020-10-21

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Introduction</h4> Emtricitabine-Tenofovir was officially approved as the first medicine for HIV pre-exposure prophylaxis (PrEP) in China on August 11, 2020. The large number of key populations who would benefit from PrEP in the context of limited health system capacity and public awareness will pose challenges for timely PrEP scale-up. This suggests an urgent need for innovative and accessibl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
78839053-e388-5f7b-8a79-4db879ea4a6d
DOI
10.1101/2020.10.19.20215400
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A community-engaged mHealth intervention to increase uptake of HIV Pre-Exposure Prophylaxis (PrEP) among gay, bisexual and other men who have sex with men in China: Study protocol for a pilot randomized controlled trialDOI 10.1101/2020.10.19.20215400
Select a neighboring publication to make it the new centre.